Voyager Therapeutics (VYGR) Revenue (2015 - 2026)

Voyager Therapeutics has disclosed Revenue across 12 years of filings, most recently posting $2.6 million for Q1 2026.

• Revenue for Q1 2026 came in at $2.6 million, down 60.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $36.6 million (down 45.45% YoY), and the FY2025 annual result was $40.4 million, down 49.53% from the prior year.
• Revenue came in at $2.6 million for Q1 2026 at Voyager Therapeutics, down from $15.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $150.5 million in Q1 2023 to a low of -$1.5 million in Q4 2022.
• The 5-year median for Revenue is $6.5 million (2025), against an average of $24.4 million.
• Across the five-year window, Revenue plunged 105.52% in 2022 and jumped 22769.3% in 2023, its largest moves.
• Voyager Therapeutics' Revenue stood at -$1.5 million in 2022, then soared by 5913.42% to $90.1 million in 2023, then slumped by 93.01% to $6.3 million in 2024, then soared by 143.99% to $15.4 million in 2025, then sank by 83.13% to $2.6 million in 2026.
• The last three Revenue figures came in at $2.6 million (Q1 2026), $15.4 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.